A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer (NCT05608044)

🧪 Interventions in This Study

• Botensilimab (DRUG)
• Balstilimab (DRUG)
• Standard of Care (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (65 Sites)

Showing the first 25 of 65 sites.

• HonorHealth Research Institute — Scottsdale, Arizona
• City of Hope National Medical Center — Duarte, California
• Keck School of Medicine of the University of Southern California — Los Angeles, California
• Rocky Mountain Cancer Center - Aurora — Aurora, Colorado
• University of Colorado — Denver, Colorado
• Medical Oncology Hematology Consultants — Newark, Delaware
• Florida Cancer Specialists and Research Institute - Lake Mary — Lake Mary, Florida
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• University of Michigan — Ann Arbor, Michigan
• Atlantic Health System - Morristown Medical Center — Morristown, New Jersey
• Weill Cornell Medicine — New York, New York
• Mount Sinai Hospital - New York — New York, New York
• Memorial Sloan Kettering — New York, New York
• Cleveland Clinic — Cleveland, Ohio
• Earle A. Chiles Research Institute - Robert W. Franz Cancer Center - Providence Cancer Institute — Portland, Oregon
• Oregon Health & Science University (OHSU) — Portland, Oregon
• Lifespan Clinical Research Center/Cancer Institute (Providence Rhode Island) — East Providence, Rhode Island
• Tennessee Oncology Nashville (Sarah Cannon) — Nashville, Tennessee
• Vanderbilt University School of Medicine — Nashville, Tennessee
• Texas Oncology - Austin Midtown — Austin, Texas
• Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
• MDACC — Houston, Texas
• Virginia Cancer Specialists/NEXT Virginia — Fairfax, Virginia
• Swedish Cancer Institute — Seattle, Washington

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Colorectal Cancer

• A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer — Phoenix, Arizona
• Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer — Toronto, Ontario
• A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) — Los Angeles, California
• A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer — Duarte, California
• A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer — Los Angeles, California
• Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation — Phoenix, Arizona

Explore by condition: All Metastatic Colorectal Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.